The company is offloading 10.5 million ordinary shares to institutional and retail buyers, with underwriters retaining a 30-day option to purchase an additional 1.58 million shares to cover over-allotments. This latest financial maneuver contributes to a broader upward trend for the stock, which has gained 10% over the last month and 15% since the start of the year.

Pending customary closing conditions, the transaction is slated to finalize on June 18. The capital infusion comes at a time when the firm is looking to strengthen its position in the competitive AI-driven diagnostics sector.